Education
About Us
Working with TipRanks
Follow Us
Iterum Therapeutics Plc (ITRM)
NASDAQ:ITRM
Earnings Data
Report Date
Aug 08, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.11Last Year’s EPS
-0.23Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: -7.92%
|Next Earnings Date:Aug 08, 2025
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in reducing operating and R&D expenses, extending the cash runway, and preparing for the potential market launch of ORLYNVAH. However, challenges include increased G&A expenses, the inability to secure a strategic partner, competition from new market entrants, and ongoing net losses. While there are positive steps toward commercialization, the balance of highlights and lowlights suggests a cautious outlook.Company Guidance
During the Iterum Therapeutics plc first quarter 2025 earnings call, the company provided guidance on several key metrics. The potential commercialization of ORLYNVAH is planned for the fourth quarter of 2025, targeting the U.S. market for uncomplicated urinary tract infections. With approximately 40 million prescriptions generated annually in the U.S., ORLYNVAH's addressable market is estimated at around 26 million prescriptions for at-risk patients. Iterum anticipates capturing a 1% market share could result in over $250 million in annual net sales. Financially, Iterum reported a reduction in operating expenses to $3.7 million for Q1 2025 from $6.2 million in the same period in 2024, with a net loss of $4.9 million on a GAAP basis. The company ended March 2025 with $12.7 million in cash and cash equivalents, with a cash runway extended into 2026, alongside recent fundraisings totaling $5.2 million in April 2025. They also highlighted the elimination of a significant amount of debt through the repayment of exchangeable notes.Decreased Operating Expenses
Total operating expenses were $3.7 million in Q1 2025, compared to $6.2 million in Q1 2024, showing a significant reduction in costs.
Reduction in R&D Expenses
R&D costs were approximately $600,000 in Q1 2025, compared to $4 million in Q1 2024, primarily due to decreased costs associated with the REASSURE trial.
Extended Cash Runway
The company has extended its cash runway into 2026, including the potential launch of ORLYNVAH by Q4 2025.
Potential Market for ORLYNVAH
The U.S. market for uncomplicated urinary tract infections is large, with 40 million prescriptions annually. ORLYNVAH could capture a market share leading to over $250 million in net sales at peak.
Repayment of Debt
In January 2025, Iterum Therapeutics repaid the outstanding principal and interest on its exchangeable notes, eliminating a significant debt liability.
---
ITRM Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ITRM Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | $1.01 | $0.94 | -6.93% |
Feb 07, 2025 | $1.49 | $1.43 | -4.03% |
Nov 14, 2024 | $1.43 | $1.36 | -4.90% |
Aug 14, 2024 | $1.17 | $1.21 | +3.42% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Iterum Therapeutics Plc (ITRM) report earnings?
Iterum Therapeutics Plc (ITRM) is schdueled to report earning on Aug 08, 2025, TBA Not Confirmed.
What is Iterum Therapeutics Plc (ITRM) earnings time?
Iterum Therapeutics Plc (ITRM) earnings time is at Aug 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ITRM EPS forecast?
ITRM EPS forecast for the fiscal quarter 2025 (Q2) is -0.11.
---